Press release
MHRA Exclusive Speaker Interview Released and ImmuneBiotech AB CEO Announced as Latest Speaker ahead of Immuno-Oncology 2018
Immuno-Oncology 2018
There’s just over 1 week to go until SMi’s Immuno-Oncology conference on 26th – 27th September 2018 in London, UK (http://www.immuno-oncology-conference.com/openpr), set to bring together an unrivalled gathering of industry leaders and scientific pioneers to explore the potential of targeted immuno-therapies.
A new session on day one has recently been announced, with Shahram Lavasani, the CEO of ImmuneBiotech AB presenting on “Could the Microbiome Boost Cancer Immunotherapy?”. Shahram will be providing his expertise and experience on the understanding of the dynamics and function of the human microbiome in health and disease, dysbiosis and cancer therapy, and microbial interventions.
In the run up to the two-day conference, SMi also caught up with Dr Andrew Exley, a Medical Assessor, for an exclusive interview to discuss his role in the MHRA, the biggest challenges and innovations in Immuno-Oncology, and what he hopes to gain from this year's meeting.
Interview Snapshot:
Q. What would you say is the biggest barrier to implementation of Immuno-Oncological therapies in common treatment plans?
A. The biggest barriers to implementation of Immuno-Oncological therapies into common treatment plans are the identification, validation and interpretation of clinically meaningful biomarkers, surrogate endpoints and clinical trial goals. Overcoming these clinical barriers has a critical role in addressing the economic concerns about Immuno-Oncology therapies.
Q. What do you think has been the greatest innovation within Immuno-Oncology over the last year or two? Where do you see Immuno-Oncology leading us over the next few years?
A. The potential and pitfalls within Immuno-Oncology are exemplified by recent developments in checkpoint blockade and CAR-T cells. Progress in targeting and optimising these therapies is anticipated.
Dr Exley is a Medical Assessor in the Biologicals and Biotechnology Unit within the Licensing Division of the MHRA in London. He provides bench to bedside expertise in immunology and regulatory affairs including diagnostics, biomarkers, and clinical endpoints, from a background of extensive experience as a consultant immunologist.
Dr Exley will also be speaking and presenting at this year's conference on "Generating Symbiosis with Regulatory Affairs in Immuno-Oncology". The full interview is now available to download on the event website’s download section at http://www.immuno-oncology-conference.com/openpr
2018 Event Highlights:
• Learn about targeting immune checkpoints with Humabody VH Therapeutics
• Discover advances in durable disease control with Keytruda as an anti-cancer therapy
• Discuss the tumour mutation burden and the potential of its use as an indication of treatment choice
• Develop an understanding of unwanted immunogenicity and functionality testing of immuno-oncology drugs
• Gain insight into new techniques, such as emerging applications of liquid biopsies
Visit the website to find out more, download the latest brochure, full speaker line-up and other exclusive content, and register your place: http://www.immuno-oncology-conference.com/openpr
About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
SMi Group
1 Westminster Bridge Rd, South Bank, London SE1 7XW
Maria Mandic
mmandic@smi-online.co.uk
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release MHRA Exclusive Speaker Interview Released and ImmuneBiotech AB CEO Announced as Latest Speaker ahead of Immuno-Oncology 2018 here
News-ID: 1249439 • Views: …
More Releases from SMi Group
Exclusive Speaker Interview with AOBiome ahead of the 22nd Pain Therapeutics Con …
SMi Reports: Exclusive speaker interview with Todd Krueger at AOBiome released for the Pain Therapeutics Conference
The pain therapeutics industry has grown at an exponential rate in recent years. The 22nd Annual Pain Therapeutics conference will cover the leading advances in pain therapeutics, exploring late development clinical trials, novel treatments for chronic conditions, technology collaboration treatments, using VR and Medical Devices that carry out non-invasive nerve stimulation.
Industry leaders will uncover the…
Exclusive Speaker Interview with Ester Lovsin Barle ahead of the 6th Annual High …
Now in its 6th year, the Highly Potent Active Pharmaceutical Ingredients conference offers you peer-to-peer networking with industry experts including heads and directors of EHS, Occupational Hygiene, Quality Assurance and more. Taking place on 9th and 10th May in London, UK.
With a key focus on expanding your community and exploring the latest developments in the industry at this two-day event, including key regulatory updates, and leading case studies from leading…
FDA Keynote Speaker at SMi's 5th Annual Pharmaceutical Microbiology East Coast C …
SMi Group Reports: Keynote FDA speaker Dr. John Arigo, to present at the 4th Annual Pharmaceutical Microbiology East Coast, taking place in just 3 weeks' time on April 27th and 28th, 2022.
With just three weeks remaining until the highly anticipated conference, SMi Group are delighted to announce a key FDA Speaker joining the 5th Annual Pharmaceutical Microbiology East Coast Conference. This event will take place on April 27th and…
Group Captain (ret'd) Robert Daisley invites you to attend Air Mission Planning …
SMi Group reports: Chairman Group Captain (ret'd) Robert Daisley of the Air Mission Planning and Support Conference cordially invites experts to join the conference in London, UK in one week.
With only one week remaining, SMi Group is delighted to publish an invitation letter for SMi's 13th Annual Air Mission Planning & Support Conference, taking place on the 6th and 7th April 2022 in London, UK from the conference chairman.
The…
More Releases for MHRA
MHRA, Pfizer, Autolus and Tusk Theraputics Sign Up for Immuno-Oncology Conferenc …
SMi Reports: Industry leaders MHRA, Pfizer, Autolus, Tusk Therapeutics, KCL, Boehringer Ingelheim and more are amongst the latest organisations to register for Immuno-Oncology 2018 (http://www.immuno-oncology-conference.com/openpr)
There’s just 2 weeks until SMi’s Immuno-Oncology conference commences in London on the 26th and 27th September. With limited places left, interested attendees are urged to book soon to avoid missing out on joining an international gathering of immuno-therapy experts at this highly-anticipated conference.
Recent Confirmed Attendees…
Talks from the MHRA, Innovate UK, Plasticell and more
The lengthening shadow of increase in health spending in the coming years is sharpening the minds of legislators, regulators and payers alike. The growing time-to-market, the rising costs in development of novel medicines, as well as the more basic drive to be ‘ahead of the game’, forces the industry and the legislators to rethink basic postulates of drug development.
The global regulatory environment is undergoing major reshape, allowing patients early access…
SMi’s Injectable Drug Delivery Releases an Exclusive Interview by NIBSC-MHRA
SMi are delighted to have interviewed our speaker Maxime Gaillot, Senior Device Engineer, Roche, for Injectable Drug Delivery!
Maxime Gaillot works for Roche since 2011. He has 15 years’ experience in the medical device and polymer industry. After some years, in the plastic closure industry, Maxime started his career in the Medical Device industry at Novartis. He worked on the development of a dual chamber pen injector and an electronic reusable…
MHRA Update: Regulatory Considerations for The Registration of New Antibacterial …
Taking place in London on 19th and 20th March 2018, the theme for SMi’s 20th annual conference on Superbugs and Superdrugs is to tackle the scientific, regulatory and economic challenges to combat AMR.
Highlights will include an exclusive keynote address from the MHRA when SMi Group welcomes the expertise of Mair Powell to provide regulatory guidance on the registration of new antibacterial agents.
Dr. Powell is a member of the EMA’s Infectious…
MHRA to Open 10th Annual European Summit on Pre-Filled Syringes
The Medicines and Healthcare Products Regulatory Agency present an opening keynote address at SMi’s 10th annual Pre-Filled Syringes Europe conference and exhibition next January.
SMi Group will welcome the expertise of Elizabeth Baker, Group Manager Licensing Division, MHRA, when she presents an opening keynote address at the 10th annual Pre-Filled Syringes Europe conference taking place on 17th and 18th January 2018 in Central London.
The upcoming talk will offer attendees with new…
MHRA & FDA to explore In Vitro Diagnostics regulations in the EU & USA
The 3rd In Vitro Diagnostics conference for SMi Group will take place in London on the 14th & 15th June 2017.
Aimed at Managers/Heads and Directors of Regulatory Affairs, In Vitro Diagnostics, Clinical Affairs and Quality Assurance, IVDs 2017 will provide regulatory updates and key industry feedback from leading IVD manufacturers within this complex and ever-changing landscape.
Through a series of presentations from handpicked industry experts and Notified Bodies, the 2017…
